Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Leading-Edge Research and In-sights of Genomics and Pharmacogenomics
- Genomics 2018

About Conference

Allied Academic Publication is an amalgamation of a few regarded scholastic and scientific  affiliations known for advancing logical disposition. Set up in the year 1997, Andrew John Publishing Group is a specific Medical distributer that works as a team with the affiliation and social orders. This distributing house has been established on the base of regarded scholastic and research organizations including The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM),The Canadian Vascular Access Association (CVAA).

Genomics  2018 welcomes every one of the members from everywhere throughout the world to go to  International Conference on Genomics and Pharmacogenomics' amid September 21-22,2018 in Philadelphia, USA which incorporates provoke keynote introductions, Oral introductions, Poster introductions and Exhibitions.

Genomics is a region within hereditary qualities ( i.e., genetics) that concerns the sequencing and examination of a creature’s genome. Genomics additionally includes the investigation of intra-genomic procedures, for example, epistasis, heterosis, and pleiotropy and the interactions between the loci and alleles inside the genome. The fields of molecular biology (subatomic science) and genetics are mostly concerned with investigation of role and function of the single genes, a noteworthy subject in today's biomedical research. By difference, genomics does not include single quality research unless the intention is to comprehend a solitary quality's belongings in setting of the whole genome. 

Genomics  2018

The conference unites assets and expertise to scaffold Genomics and Pharmacogenomics to unveil noteworthy worldwide disclosures in Human Health. It gives an awesome stage to cover recent breakthroughs in Genomics, Pharmacogenomics, Bioinformatics, Plant Genomics, new genomic apparatuses and its partnered territories. The theme of the gathering will focus on making an interpretation of genomic advances into Human Benefits and to address current trends in Genomics for better future. For more points of interest please visit: With individuals from around the globe concentrated on learning about Genomics and Pharmacogenomics and its advances; this is your best chance to achieve the biggest amalgamation of members from the Genomics and its partnered territories. Direct introductions, disseminate data, meet with present and potential researchers, make a sprinkle with new medication advancements, and get name acknowledgment at this 2-day occasion. Widely acclaimed speakers, the latest strategies, improvements, and the freshest updates in Genomics and Pharmacogenomics are signs of this conference.

Genomics  2018 respects every one of the participants, speakers, supports, explore specialists and business experts from everywhere throughout the world to the " International Conference on Genomics and Pharmacogenomics" (Genomics 2018) which will be held amid September 21-22, 2018 in Philadelphia, USA. We are regarded to welcome all of you to trade and offer your perspectives and experience on Genomics: Targeting the underlying foundations of Genomics Cells-2018.

Target Audience:

  • Genomics Students
  • Genomics Researchers
  • Genomics Faculty
  • Genomics Scientists
  • Genomics Colleges
  • Pharmacology Scientists
  • Pharmacology Health Professionals
  • Genetics Associations and Societies
  • Geneticists
  • Genetic Counselors
  • Bio-pharmacists
  • Business Entrepreneurs
  • Training Institutes
  • Software developing companies
  • Data Management Companies

Conference highlights

  • Cancer Genomics
  • Techniques used in genomics
  • Structural Genomics
  • Functional genomics
  • Epigenomics and Epigenetics
  • Pharmacogenomics
  • Personalized  and Regenerative medicine
  • Clinical Genomics
  • Bio marker
  • Micro array technology
  • Inherited Metabolic Disorder
  • Genomic Instability
  • Bioinformatics and Computational biology
  • Comparative Genomics
  • Animal Genetics and Genomics
  • Plant Genomics and Molecular Pharming
  • Genome Engineering
  • Genomic medicine
  • Innovation in Genomics
  • Future trends in Pharmacogenomics

Welcome Label

Genomics 2018 respects every one of the participants, speakers, supports, sponsors and business experts from everywhere throughout the world to the " International Conference on Genomics and Pharmacogenomics" (Genomics 2018) which will be held amid September 21-22, 2018 in Philadelphia, USA. We are regarded to welcome all of you to trade and offer your perspectives and experience on Genomics: Targeting the underlying foundations of Genomics Cells-2018.

Allied Academics sorts out Genomics 2018 conference along with 300+ Conferences across USA, Europe and Asia consistently with support from 1000 more scientific social orders and publishes 400+ Open access journals which contains more than 30000 famous identities as publication board individuals.

We welcome you to go along with us at the Genomics 2018, where you will make sure to have a significant involvement with researchers from around the globe. All individuals from the Genomics 2018 organizing committee looking forward to  meeting you in  Philadelphia , USA.


Sessions and Track

Allied Academies International Conferences welcomes every one of the members from everywhere throughout the world for the International Conference on Genomics and Pharmacogenomics on September 21-22, 2018 at Philadelphia, USA which incorporates incite keynote presentations, oral presentations, poster presentations and exhibitions.

Track 1: Cancer genomics

Cancer (malignancy) Genomics is the investigation of hereditary transformations in charge of disease, utilizing genome sequencing and bioinformatics. Clinical genomics is to enhance cancer treatment and results lies in figuring out which sets of qualities and quality communications influence diverse subsets of growths. Global Cancer Genome Consortium (ICGC) is a willful logical association that gives a gathering to joint effort among the world's driving disease and genomic specialists.

Track 2: Techniques used in genomics

Genomics deals with structure, function, evolution and mapping of genomes. There are many techniques in genomics which includes Genomic DNA isolation, DNA separation, Cloning and vectors, detection of genes of interest and so on. These techniques are very much useful in the field of medicine to diagnose infectious diseases and are also used in forensics, agriculture.

Track 3: Structural Genomics

Structural Genomics endeavors to determine the 3 Dimensional structure of each protein encoded by the genome and used to foresee novel protein folds based on other structural data. It can likewise take the upside of complete genome sequence in order to decide protein structure. The gene sequence of the target protein can be compared with a known sequence and information of the structure can be gathered from known protein structure.

Track 4: Functional genomics

Functional Genomics utilize tremendous abundance of information delivered by genomic and transcriptomic tasks to depict gene functions and interactions. Drifts in Functional Genomics are, Affymetrix, raised as an early trailblazer around there by creating a useful approach to analyze gene function as a framework. Nimble Gen Systems and Febit, are creating manufactured micro-arrays that are delivered utilizing a smaller scale reflect based, veil less framework.

American Society of Transplant Surgeons Up to $100,000 every year ($50,000 in real money and up to $50,000 in-kind) for 2 years. For the purpose of this grant, in-kind support is restricted to the cost of tests. Research of Genomics Market in the US (2014- 2018) and Global Genomics Market (2014-2018) reports to its store. Useful Genomics showcase in the US is figure to develop at a CAGR of 7.28% over the period 2013-2018 while the worldwide genomics industry is anticipated to develop at 11.21% CAGR amid a similar time.

Track 5: Epigenomics and Epigenetics

Epigenomics is the investigation of the total arrangement of epigenetics alterations on the hereditary material of a cell, known as the epigenome. Epigenetic changes are reversible adjustments on DNA or histones that influence quality expression without modifying the DNA sequence. Epigenomics upkeep is a consistent procedure and assumes an imperative part in security of eukaryotic genomes by participating in critical organic systems like DNA repair. Plant flavones are said to be repressing epigenomic marks that cause cancers. Two of the most portrayed epigenetic alterations are DNA methylation and histone adjustment.

Epigenetic adjustments assume an imperative part in quality expression and control, and are included in various cell procedures, for example, in separation/advancement and tumorigenesis.

Track 6: Pharmacogenomics

Pharmacogenomics is the investigation of how genes influence a man’s reaction to drugs. This is generally a new field consolidates pharmacology(investigation of medications) and genomics(the investigation of genes and their capacities) to create successful, safe pharmaceuticals and dosages that will be custom fitted to a man’s hereditary makeup. Computational advances in Pharmacogenomics  has turned out to be a gift in research. 

These genetic differences are utilized to prevent from adverse drug reactions and to predict whether a medication will be effective for a specific individual. In the future, Pharmacogenomics will be used for the development of tailored drugs to treat wide range of health issues such as, cardiovascular diseaseAlzheimer disease , cancer, HIV/AIDS, and asthma.

Significant Universities managing Pharmacogenomics are: Harvard University, US,  University of Cambridge, UK, National University of Singapore, Singapore, University of Oxford, UK, Karolin ska Institute, Sweden, Monash University, Australia, Imperial College London, UK, University of Tokyo, Japan, University of Melbourne, Australia, University of Michigan, US. 

Track 7Personalized regenerative medicine

Personalized medicine as a novel field of medicine based on Pharmacogenetics and Pharmacogenomics information used for the prescription of specific therapeutics procedure for an individual and it also covers many fields of healthcare. Accordingly Regenerative medicine and cellular therapy are the new areas of medicine use cell based products to develop personalized treatments. iPSCs and individual pleuripotent stemcells are the appropriate candidates introduced for the personalized therapies.

 Track 8: Clinical genomics

Clinical genomics is the utilization of genome sequencing to inform patient diagnosis and care and it is a quickly evolving field. Learning of the human genome is a long way from finish, however there are as of now uses for hereditary and genomic data in the center. Genome sequencing is relied upon to have the most effect in describing and diagnosing uncommon and acquired infections, stratifying people's tumors to guide treatment (exactness drug), giving data around a person's danger of creating ailment or their imaginable reaction to treatment (wellbeing administration)

The International Standards for Cytogenomic Arrays (ISCA) Consortium, of which OGT is a section, is a creating social event of sub-nuclear innate qualities labs adequately working towards improving human administrations through the establishment of principles for sub-nuclear testing, including the generation of standardized a CGH groups for clinical inherited qualities explore. The Cancer Cytogenomic Micro array Consortium (CCMC) is a near social event, starting late settled with the goal of growing the points of interest given by microarrays to threat investigate. These social occasions continue working towards outlining out a course of action of rules to ensure that sub-nuclear strategies improve and overhaul the organizations given by clinical research labs.

Track 9: Biomarker

A biomarker, or natural marker, is a measurable indicator of some biological state or condition. A biomarker is a test that can be utilized to assist analyze a condition or to help screen a condition or reaction to treatment. They are utilized as a part of numerous ranges of medication both in standard therapeutic practice and furthermore in research, particularly in clinical trials. In drug, a biomarker can be a traceable substance that is brought into a life form as a way to analyze organ work or different parts of wellbeing. For instance, rubidium chloride is utilized as a radioactive isotope to assess perfusion of heart muscle.

Biomarkers keep on becoming progressively significant in research and social insurance applications, as confirm by the worldwide market for items required in their ID, approval, and utilize anticipated to achieve USD 53.34 Billion by 2021 from USD 27.95 Billion in 2016, developing at a CAGR of 13.8% amid the conjecture time frame (2016–2021).

Track 10: Micro array technology

Micro array is a tool used in laboratory to detect the expressions of thousands of genes at the same time. Micro array technology has extensive application in Pharmacogenomics. Comparative analysis of the genes from a diseased and a normal cell will help to identify the biochemical constitution of the proteins which are synthesized by the diseased genes. The researchers can use this information for synthesizing drugs that combat with these proteins and reduce their effect.

DNA micro array technology helps in the identification of new genes, to learn more about the diseases like heart diseases, mental illness, infectious disease and especially the study of cancer. 

Track 11: Inherited Metabolic disorders

Inherited metabolic disorders (IMD) result from mutations of genes associated with metabolism, co factors, channels, carriers or receptors in metabolic pathways that are the basis of metabolic disorders of anabolic or catabolic pathways. These mutations could also be responsible for different types of biochemical abnormalities, including the accumulation of intermediate and/or bypass metabolites, or a deficiency of terminal metabolites, leading to metabolic crises, such as lactic acidosis, hyperammonemia syndrome and ketoacidosis. Genotype-phenotype correlations based on expression analysis of structural and functional mutations are gradually being recognized in different IMDs and subtypes of the disease, and >500 types of IMD have been identified so far. In all regions, it is reported that the overall incidence of neonatal with IMD is 1 in 1,000–2,500 newborns, while an estimated 16–20 million newborns are confirmed in China each year, indicating that effective and applicable measures are warranted due to the high-risk of infant IMD.

Track 12: Genomic instability

Genomic instability is a mechanism in which a high frequency of mutation occurs inside the genome of a cellular lineage. These mutations include changes in DNA and RNA sequences, chromosomal rearrangements (aneuploidy).  One of the sources of genomic stability is the high frequency of externally caused DNA damage since DNA damages can cause inaccurate translesion synthesis past the damages or errors in repair, leading to mutation. Another source of genome instability may be mutational reductions in expression of DNA repair genes. DNA repair is likely an important source of genome instability. The procedure of hereditary instability prompts aneuploidy, in which the cells introduce a chromosomic number that is either higher or lower than the normal complement for the species.

Track 13: Bioinformatics and Computational biology

Bioinformatics is the investigation of gathering and dissecting complex organic information, for example, hereditary codes. Atomic medication requires the reconciliation and examination of genomic, sub-atomic, cell, and also clinical information and it hence offers an astounding arrangement of difficulties to bioinformatics. Bioinformatics these days has a basic part both, in interpreting genomic, transcriptomic, and proteomic information produced by high-throughput test advancements. The Canadian government is likewise making good money for omics research, with the Canada Foundation for Innovation backing several tasks as a component of a C$30.4 million ($27.6 million) interest in scholarly research. Computational biology is the science of using biological data to develop relations and algorithms among various biological systems.

Track 14: Comparative genomics

To begin with, the tremendous quantities of species and the considerably bigger size of few genomes make the entire sequencing of all genomes, a non-ideal approach for understanding genome structure. Second, within a given species most people are genetically distinct in various ways. What does it really mean, for instance, to "sequence a human genome"? The genomes of two people who are hereditarily distinct differ with respect to DNA sequence. These two issues, and the potential for other novel applications, have offered ascend to new methodologies which, taken together, constitute the field of relative genomics. Agriculture is the field that receives the rewards of comparative genomics. Recognizing the loci of favorable genes is a key stride in rearing harvests that are enhanced for greater yield. 

Track 15: Animal Genetics and Genomics

Animal Genetics examines the heredity and variations in animals.Animals have independent inheritance of characters as a result of their substantial number of chromosomes. Hybrid Analysis is the key strategy to study the inheritance of characters and it decides the idea of numerous morphological, physiological and biochemical characteristics which much of the time depend just on one of a few sets of genes.

Track 16: Plant genomics and Molecular Pharming

 Molecular Pharming utilizes plants to create substantial amounts of pharmaceutical substances like antibodies and vaccines. It is as same as the technique for creating Genetically Modified Crops, the artificial introduction of genes into plants.National Science Foundation (NSF) announces its intention to support plant genome research through the Plant Genome Research Program (PGRP). Plant Genomics Research Program (PGRP) awards from the National Science Foundation (NSF) that NSF offers supplements to support research collaboration with scientists in developing countries. The intent of Developing Country Collaborations in Plant Genome Research (DCC-PGR) awards is to support collaborative research linking U.S. researchers with partners from developing countries to solve problems of mutual interest in agriculture, energy and the environment, while placing U.S. and international researchers at the center of a global network of scientific excellence.

Track 17: Gene Editing and Genome Engineering

Genome designing implies the techniques and strategies created in recent years for the targeted, particular change of the genetic data or genome of living beings. It speaks to an extremely dynamic field of research as a result of the extensive variety of conceivable applications, the creation of remedial proteins, the disposal of constant viral arrangements, farming biotechnology, the improvement of new eras of hereditarily altered plants and for the advancement of research instruments for instance, to investigate the capacity of a gene.

The CRISPR-cas9 framework makes gene editing in numerous living beings and cells like our own egg, sperm or embryo more proficient, accessible and straightforward than at any other time. These noteworthy abilities have spawned discussions encompassing the morals and uses of the new framework, and have gathered huge consideration around the globe to guarantee ethically correct usage.

Track 18: Genomic medicine

Genomic medicine is characterized as a rising medicinal teach that includes utilizing genomic data around a person as a major aspect of their clinical care (e.g., for analytic or remedial basic leadership) and the well-being results and strategy ramifications of that clinical utilize. As of now, genomic solution is having an effect in the fields of oncology, pharmacology, uncommon and undiscovered ailments, and irresistible ailment.

The NHGRI Genomic Medicine Working Group (GMWG) has been social occasion master partners in a progression of genomic solution gatherings to examine issues encompassing the appropriation of genomic drug. Furthermore the working gathering gives direction to the National Advisory Council on Human Genome Research (NACHGR) and NHGRI in different zones of genomic medication usage, for example, laying out infrastructural requirements for reception of genomic solution, recognizing related endeavors for future coordinated efforts, and exploring progress generally speaking in genomic drug execution.

Sans cell circling DNA is additionally being investigated as a bio marker for tumors. As tumor cells bite the dust they discharge pieces of their transformed DNA into the circulation system. Sequencing this DNA can give bits of knowledge into the tumor and conceivable medications, and even be utilized to screen tumor movement (as a contrasting option to obtrusive biopsies).

At present, more than 100 FDA-endorsed drugs have pharmacogenomics data in their names, in differing fields, for example, analgesics, antivirals, cardiovascular medications, and hostile to growth therapeutics. 

Track 19: Innovation in genomics

The field of pharmaceutical is significantly changed by new innovations; a lot of this change originates from energizing advances in genomics. Innovations, for example, fluid biopsies have been created that can identify disease DNA even in the initial stage after its entry. Specialists likewise have found five epigenetic marks for malignancy, and we can anticipate that more will come.Today, on the off chance that one needs to approach a comprehensive way to deal with medication in view of genomic comprehension, it implies putting around $2,000 in one's own particular well being

Track 20: Future trends in Pharmacogenomics

Around 80% of useful qualities in the human genome are communicated in the mind and more than 1,200 unique qualities have been related with the parthenogenesis of CNS issue and dementia. Pharmacogenetics investigations of psychotropic medication reaction have concentrated on deciding the connection between varieties in particular hopeful qualities and the positive and unfriendly impacts of medication treatment. Around, 18% of neuroleptics are substrates of CYP1A2 proteins, 40% of CYP2D6, and 23% of CYP3A4; 24% of antidepressants are substrates of CYP1A2 compounds, 5% of CYP2B6, 38% of CYP2C19, 85% of CYP2D6, and 38% of CYP3A4; 7% of benzodiazepines are substrates of CYP2C19 chemicals, 20% of CYP2D6, and 95% of CYP3A4. 10-20% of Western populaces are inadequate in qualities of the CYP superfamily and the pharmacogenomics reaction of psychotropic medications likewise relies on upon hereditary variations related with dementia. Imminent reviews with hostile to dementia drugs or with multifactorial methodologies have uncovered that the helpful reaction to customary medications in Alzheimer's ailment is genotype-particular.


Market Analysis

Genomics is a discipline which breaks down the capacity and structure of genomes. It utilizes different inspecting, sequencing, and information examination and elucidation systems to interpret, amass, and break down genomes. The learning of finish set of DNA recognizes certain hereditary infections, grow best course of treatment, and add to accuracy prescription.

With the huge decline in the sequencing expenses and rising interests in the pharmaceutical business, the worldwide genomics market is estimate to develop at a CAGR of 15.1% to be worth $19,938.6 million by 2020.

This development is additionally determined by the mechanical advancements in bioinformatics, expanding clinical capacities, and all the more clinically pertinent sequencing timescales. Be that as it may, need of huge clinical speculation, absence of subsidizing in the developing markets, rising union mostly in the instruments advertise, and moral and lawful difficulties will go about as an imperative to industry development amid the estimate time frame.

The worldwide genomics market is divided by techniques, innovation, instruments, consumables, administrations, and geology. The genomics business is still at a beginning stage with numerous undiscovered markets exhibit over the globe. In any case, the sequencing technique is generally at a develop arrange, particularly, in the created markets. As, the size of genomes information develops, the information investigation and elucidation market is relied upon to develop at a noteworthy rate soon. Cutting edge DNA sequencing (NGS) innovation has changed biomedical research, making genome and RNA sequencing a moderate and regularly utilized instrument for a wide assortment of research applications. Therefore, the market has been worried to deal with the gigantic information yield from this procedure. Hence, the unpredictability and sheer measure of information created by NGS has prompted a requirement for genomic focuses to shape bioinformatics groups so as to dissect the yield information.

North America is the significant market in the worldwide genomics advertise and is relied upon to command this market amid the figure time frame, with the U.S. contributing a noteworthy offer, trailed by Europe, and Asia-Pacific. Then again, the Asian market, particularly India and China, is relied upon to witness a lift sought after for genomics showcase amid the estimate time frame, thus of their monetary improvement, expanding hereditary innovative work exercises, radically diminished mass scale hereditary testing costs, and the developing concentration of the real players in this district.

The key players in the worldwide genomics market are Affymetrix, Inc., Agilent Technologies, BGI (Beijing Genomics Institute), Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Cepheid, GE Healthcare, Qiagen N.V, Roche Holding AG, Pacific Biosciences of California, Inc., Oxford Nanopore Technologies Ltd., Beckman Coulter Genomics, Inc., Perkin Elmer, Inc., DNASTAR, Inc, Genomatix Software Gmbh, and GenoLogics Life Sciences Software, Inc.,

Stakeholders of the genomics market :

Genomics instrument/systems manufacturing company

Suppliers and distributors of genomic instrument/systems and consumables

Hospitals, diagnostic centers and medical colleges

Research institutes  

Teaching hospitals and academic medical centers(AMC)

 Pharmaceutical or bio pharmaceutical companies

Business research 

Target Audience:

Industry        40%

Academia     50%
Others          10%


Genomics Sequencing Technologies Market

Research Application       43%

Healthcare Application    39%

Commercial Application   18%


Genomics Related Societies

American Society of Human Genetics

European Society of Human Genetics

Japan Society of Human Genetics

Genetic Society in China

Human Genome Variation Society

Environmental Mutagenesis and Genomics Society

International Genome Consortium

University of California Conservation Genomics Consortium

Top Universities

Technical University of Munich

University of Würzburg
University Medical Center
University of Tubingen
Universitätsklinikum Münster
Technische Universität Dresden
Leipzig University
University Medicine of Rostock
Institut fur Humangenetik und Anthropologie der Universitat
Otto-von-Guericke University
Hannover Medical School
Max Planck Institute

European Society of Human Genetics:
Armenian Society of Human Genetics
Austrian Society of Human Genetics
Belgian Society of Human Genetics
British Society of Genetic Medicine
Bulgarian Society of Human Genetics
Clinical Genetics Society of Croatia
Croatian Society of Human Genetics
Cyprus Society of Human Genetics
Czech Society of Medical Genetics
Danish Society of Medical Genetics
Dutch Society of Human Genetics
Dutch Society for Laboratory Specialist Clinical Genetics
Dutch Society of Clinical Genetics
Estonian Society of Human Genetics
Finnish Society of Medical Genetics
French Association of Genetic Counselors
French Federation of Human Genetics
French Society of Human Genetics
Genetics Society of Israel
Georgian Society of Medical Genetics and Epigenetics
German Society of Human Genetics
Hellenic Association of Medical Geneticists
Human Genetic Society of Bosnia and Herzegovina
Hungarian Society of Human Genetics
Icelandic Human Genetics Society
Irish Society of Human Genetics
Italian Society of Human Genetics
Latvian Association of Human Genetics
Latvian Society of Medical Genetics
Lithuanian Society of Human Genetics
Macedonian Society of Human Genetics
Malta College of Pathologists, Human Genetics Group
Medical Genetics Society of Israel
Norwegian Society of Human Genetics (NSHG)
Norwegian Society of Medical Genetics
Polish Society of Human Genetics
Portuguese Society of Human Genetics
Romanian Society of Human Genetics

Funding Agencies:

Alexander von Humboldt Foundation
Deutsche Forschungsgemeinschaft (DFG)
Federal Ministry of Education and Research (BMBF)
German Academic Exchange Service (DAAD)
Max-Planck Gesellschaft
Scientific Stay for Canadians in France
French National Institute of Health and Medical Research (INSERM)
German Academic Exchange Service
German Research Foundation (Deutsche Forschungsgemeinschaft
The National Research Council (CNR)
The Netherlands Organization for Scientific Research (NWO)
Royal Netherlands Academy of Arts and Sciences (KNAW)
Swiss National Science Foundation



Organizing Committee
OCM Member
Henry M Sobell
University of Rochester
Rochester, USA
Renowned Speakers

To Collaborate Scientific Professionals around the World

Conference Date September 21-22, 2018
Speaker Oppurtunity Day 1
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Sponsorship Opportunities Click here for Sponsorship Opportunities

Philadelphia, USA

Join The Discussion

Contact Desk


Christina Williams|Program Manager

+1 800-858-2189


Christina Williams|Program Manager

+1 800-858-2189


Christina Williams|Program Manager

+1 800-858-2189

Special Issues
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
Media Partners
Copyright © 2017-2018 Allied Academies, All Rights Reserved.